Review of the scientific literature on drivers and barriers of seasonal influenza vaccination coverage in the EU/EEA
The report aims to provide a critical review of evidence on the barriers and drivers of seasonal influenza vaccination coverage in the EU/EEA. The report focuses on high-risk groups where high coverage of seasonal flu vaccination is most important. The 2009 Council of the European Union Recommendation on seasonal influenza vaccination encourages countries to implement measures that would increase seasonal influenza vaccination uptake to at least 75% for defined older age groups, and, if possible, for other risk groups. In support of this, the ECDC report summarises the evidence on what are the barriers and what are the drivers for seasonal influenza vaccination by each risk group
Expert opinion on priority risk groups for influenza vaccination
This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.
ECDC Vaccine Scheduler
The Vaccine Scheduler is an interactive tool that shows vaccination schedules for individual EU/EEA countries and specific age groups. With this tool comparisons can be made for vaccination schedules between two countries or by disease for all or a selection of countries.
- Hepatitis A
- Hepatitis B
- Human papillomavirus infection
- Influenza in humans, seasonal
- Invasive Haemophilus influenzae disease
- Meningococcal disease
- Pneumococcal disease
- Prevention and control
- Rotavirus infection
- Tick-borne diseases
Factsheet about seasonal influenza
Influenza is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness, and at times can lead to death. The best way to prevent flu is by getting a flu vaccine each year.
Types of seasonal influenza vaccine
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers. The inactivated influenza vaccines available in the EU/EEA may contain either split virion influenza virus products or subunit influenza products.
Co-circulation of influenza a(H1N1)pdm09 and influenza a(H3N2) viruses, world health organization (WHO) european region, october 2018 to february 2019
Segaloff, H., Melidou, A., Adlhoch, C., Pereyaslov, D., Robesyn, E., Penttinen, P., Olsen, S.J.